低风险分化型甲状腺癌患者腺叶消融与补全甲状腺切除术的倾向性评分匹配结局分析:中位随访11年
研究比较低风险分化型甲状腺癌患者初始半甲状腺切除后接受放射性碘腺叶消融(RAILA)与补全甲状腺切除术的长期结局。1243例患者中514例接受RAILA、729例接受补全甲状腺切除术后残余消融,中位随访11.4年,两组复发率无显著差异,RAILA组首次131I消融率较低但无永久性低钙血症或喉返神经麻痹,放射性甲状腺炎更多见。
要点
- 低风险分化型甲状腺癌患者中,RAILA组与补全甲状腺切除组的复发率无显著差异(1.6% vs 1.0%,p=0.343)。
- RAILA组首次131I消融率为75.3%,低于补全甲状腺切除组的84.1%(p<0.001)。
- RAILA组无永久性低钙血症和喉返神经麻痹,补全甲状腺切除组分别为10/729(1.4%)和5/729(0.7%)。
核心结论
- 在剩余甲状腺叶无宏观恶性证据的低风险分化型甲状腺癌患者中, upfront RAILA被视为一种非侵入、安全且有效的补全甲状腺切除术替代方案。
研究设计与样本
- 收集1996年至2015年间接受初始半甲状腺切除、随后接受补全甲状腺切除术或RAILA的低风险分化型甲状腺癌患者数据进行分析。
- 共纳入1243例患者(中位年龄34岁,范围5-78岁),其中514例接受 upfront RAILA,729例接受补全甲状腺切除术后残余消融。
- 采用倾向性评分匹配分析验证结局,生成497对匹配 pairs。
主要发现
- 首次131I周期后消融率:RAILA组75.3% [95%CI 71.3-78.9] vs 补全甲状腺切除组84.1% [95%CI 81.2-86.6],p<0.001。
- 中位随访11.4年(四分位距8.3-15.8),复发率两组无显著差异:RAILA组1.6% [95%CI 0.7-3.2] vs 补全甲状腺切除组1.0% [95%CI 0.4-2.1],p=0.343。
- 10年无复发生存率的乘积限估计:RAILA组98.6% [95%CI 97.6-99.6%] vs 补全甲状腺切除组99.1% [95%CI 98.3-99.9%],p=0.391。
- 497对倾向性评分匹配 pairs 的结局相似。
- RAILA组无患者发生永久性低钙血症或喉返神经麻痹,补全甲状腺切除组对应发生率分别为10/729(1.4%)(p=0.006)和5/729(0.7%)(p=0.080)。
临床怎么用
- 原文结论认为,在剩余甲状腺叶无宏观恶性证据的低风险分化型甲状腺癌患者中, upfront RAILA是补全甲状腺切除术的一种非侵入、安全且有效的替代方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Radioactive iodine lobar ablation (RAILA) of the contralateral thyroid lobe has been suggested as an alternative to completion thyroidectomy in patients of differentiated thyroid cancer (DTC) who underwent initial hemithyroidectomy. However, data on long-term outcomes are scarce. In this study, we intended to describe the long-term outcomes of RAILA versus completion thyroidectomy in a cohort of low-risk DTC patients. Methods: Data of patients with low-risk DTC who underwent initial hemithyroidectomy, and were subsequently treated with either completion thyroidectomy or RAILA between 1996 and 2015, were collected and analyzed. The treatment outcomes included ablation rate, recurrence rate, recurrence-free survival (RFS), and adverse events, and were validated by propensity score matching analysis. Results: Of the 1243 patients (median age: 34 years, range: 5-78) with low-risk DTC, 514 patients underwent upfront RAILA while 729 patients underwent completion thyroidectomy followed by remnant ablation. The ablation rate following the first radioactive iodine (131I) cycle was 75.3% [95% confidence interval (CI) 71.3-78.9] in the RAILA group versus 84.1% [CI 81.2-86.6] in the completion thyroidectomy group (p < 0.001). Over median follow-up of 11.4 years (interquartile range: 8.3-15.8), the recurrence rates between the two groups were not significantly different (1.6% [CI 0.7-3.2] vs. 1.0% [CI 0.4-2.1], respectively, p = 0.343). The product limit estimate of RFS at 10 years was 98.6% [CI 97.6-99.6%] in the RAILA group versus 99.1% [CI 98.3-99.9%] in the completion thyroidectomy group (p = 0.391). The outcomes in 497 matched pairs generated through propensity score analysis were similar. None of the patients in the RAILA group experienced permanent hypocalcemia or recurrent laryngeal nerve palsy, while the corresponding rates in the completion thyroidectomy group were 10/729 (1.4%) (p = 0.006) and 5/729 (0.7%) (p = 0.080), respectively. Radiation thyroiditis was seen in 25/514 (4.9%) patients in the RAILA group versus 3/729 (0.4%) in the completion thyroidectomy group (p < 0.001). Conclusions: Upfront RAILA is seen to be a noninvasive, safe, and effective alternative to surgical completion thyroidectomy in low-risk DTC patients in the absence of macroscopic malignancy in the remaining thyroid lobe.
引用
- Bal C, Satapathy S, Tupalli A, et al. Propensity Score Matched Outcome Analysis of Lobar Ablation Versus Completion Thyroidectomy in Low-Risk Differentiated Thyroid Cancer Patients: Median Follow-Up of 11 Years. Thyroid. 2022. PMID: 35983596. doi:10.1089/thy.2022.0234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。